PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy

被引:89
|
作者
Li, Qian [1 ]
Han, Jingjing [1 ]
Yang, Yonglin [2 ]
Chen, Yu [1 ]
机构
[1] Nanjing Med Univ, Affiliated Hosp 1, Dept Anesthesiol, Nanjing, Peoples R China
[2] Nanjing Med Univ, Affiliated Taizhou Peoples Hosp, Dept Infect Dis, Taizhou, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词
PD-1; inhibitor; PD-L1; hepatocellular carcinoma; immune checkpoint; tumor immune escape; immunotherapy; REGULATORY T-CELLS; TUMOR-ASSOCIATED MACROPHAGES; TREMELIMUMAB PLUS DURVALUMAB; PD-1; BLOCKADE; OPEN-LABEL; CANCER; EXPRESSION; SORAFENIB; THERAPY; MECHANISMS;
D O I
10.3389/fimmu.2022.1070961
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hepatocellular carcinoma (HCC) has a high prevalence and mortality rate worldwide. Sorafenib monotherapy has been the standard of first-line treatment for advanced HCC for a long time, but there are still many shortcomings. In recent years, with the deepening of research on tumor immune microenvironment, researchers have begun to explore new approaches in immunotherapy, and the introduction of immune checkpoint inhibitors has brought fundamental changes to the treatment of HCC. Programmed cell death protein 1 (PD-1) is an immune checkpoint molecule that plays an important role in down-regulating immune system function and promoting tolerance. Programmed cell death ligand 1 (PDL-1) is involved in tumor immune evasion by binding to PD-1, resulting in failure of treatment. Currently, immunotherapy targeting the PD-1/PD-L1 axis has achieved unprecedented success in HCC, but it also faces great challenges, with its low remission rate still to be solved. For most patients with HCC, the PD-1/PD-L1 pathway is not the only rate limiting factor of antitumor immunity, and blocking only the PD-1/PD-L1 axis is not enough to stimulate an effective antitumor immune response; thus, combination therapy may be a better option. In this study, changes in the immune microenvironment of HCC patients were reviewed to clarify the feasibility of anti-PD-1/PD-L1 therapy, and a series of monotherapy and combination therapy clinical trials were summarized to verify the safety and efficacy of this newly developed treatment in patients with advanced HCC. Furthermore, we focused on hyperprogressive disease and drug resistance to gain a better understanding of PD-1/PD-L1 blockade as a promising treatment.
引用
收藏
页数:17
相关论文
共 50 条
  • [41] Immunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
    Chardin, Laure
    Leary, Alexandra
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [42] The roles of PD-1/PD-L1 in the prognosis and immunotherapy of prostate cancer
    Xu, Yichi
    Song, Gendi
    Xie, Shangdan
    Jiang, Wenxiao
    Chen, Xin
    Chu, Man
    Hu, Xiaoli
    Wang, Zhi-Wei
    MOLECULAR THERAPY, 2021, 29 (06) : 1958 - 1969
  • [43] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Lipson, Evan J.
    Lilo, Mohammed T.
    Ogurtsova, Aleksandra
    Esandrio, Jessica
    Xu, Haiying
    Brothers, Patricia
    Schollenberger, Megan
    Sharfman, William H.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [44] Incidence of Hyper Progressive Disease in Combination immunotherapy and anti-PD-1/PD-L1 Monotherapy for unresectable Hepatocellular Carcinoma
    Aoki, Tomoko
    Kudo, Masatoshi
    Ueshima, Kazuomi
    Morita, Masahiro
    Chishina, Hirokazu
    Takita, Masahiro
    Hagiwara, Satoru
    Ida, Hiroshi
    Minami, Yasunori
    Tsurusaki, Masakatsu
    Nishida, Naoshi
    LIVER CANCER, 2024, 13 (01) : 56 - 69
  • [45] Efficacy of PD-1/PD-L1 Immune Checkpoint Inhibitors for Advanced NSCLC According to PD-L1 Expression: A Meta-Analysis
    Ma, K.
    Guo, Y.
    Wang, Y.
    Wang, X.
    Xu, Y.
    Sun, C.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S584 - S584
  • [46] PD-1/PD-L1 in disease
    Kuol, Nyanbol
    Stojanovska, Lily
    Nurgali, Kulmira
    Apostolopoulos, Vasso
    IMMUNOTHERAPY, 2018, 10 (02) : 149 - 161
  • [47] A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now
    Bellmunt, Joaquin
    Powles, Thomas
    Vogelzang, Nicholas J.
    CANCER TREATMENT REVIEWS, 2017, 54 : 58 - 67
  • [48] Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade
    Pang, Kun
    Shi, Zhen-Duo
    Wei, Liu-Ya
    Dong, Yang
    Ma, Yu-Yang
    Wang, Wei
    Wang, Guang-Yue
    Cao, Ming-Yang
    Dong, Jia-Jun
    Chen, Yu-Ang
    Zhang, Peng
    Hao, Lin
    Xu, Hao
    Pan, Deng
    Chen, Zhe-Sheng
    Han, Cong-Hui
    DRUG RESISTANCE UPDATES, 2023, 66
  • [49] A combination of PD-1/PD-L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy
    Kong, Xianbin
    Lu, Peng
    Liu, Chuanxin
    Guo, Yuzhu
    Yang, Yuying
    Peng, Yingying
    Wang, Fangyuan
    Bo, Zhichao
    Dou, Xiaoxin
    Shi, Haoyang
    Meng, Jingyan
    MOLECULAR MEDICINE REPORTS, 2021, 23 (05)
  • [50] Molecular Biomarkers of Response to PD-1/PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer
    Tu, Megan M.
    Ng, Terry L.
    De Jong, Horns C.
    Zuiverloon, Tahlita C. M.
    Fazzari, Francesco G. T.
    Theodorescu, Dan
    BLADDER CANCER, 2019, 5 (02) : 131 - 145